Increased expression of sialyl Lewis(x) antigen as a prognostic factor in patients with stage 0, I, and II gastric cancer

Cancer Lett. 2002 Jan 25;175(2):213-21. doi: 10.1016/s0304-3835(01)00705-4.

Abstract

Immunohistochemically detected expression of sialyl Lewis(x) (Le(x)) antigen was analyzed in 101 stage 0-II gastric cancers to clarify its prognostic value after curative gastrectomy. Patients with a high-expression of sialyl Le(x) antigen within their tumors had shorter disease-specific intervals than those with negative- or low-expressing tumors (P<0.0001). This difference was noted particularly in stage I-B or II disease. Multivariate Cox's regression analysis revealed sialyl Le(x) antigen expression to be an independent predictor of disease-specific survival (Hazard ratio=9.10). In conclusion, the increased expression of sialyl Le(x) antigen may serve as a prognostic factor after curative surgery for stages 0-II gastric cancer.

MeSH terms

  • Humans
  • Lewis Blood Group Antigens / genetics*
  • Neoplasm Staging
  • Oligosaccharides / biosynthesis*
  • Prognosis
  • Sialyl Lewis X Antigen
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / pathology*
  • Survival Rate
  • Time Factors

Substances

  • Lewis Blood Group Antigens
  • Oligosaccharides
  • Sialyl Lewis X Antigen